IL-27 in tumor immunity and immunotherapy

Trends in Molecular Medicine

Volumn 19, Issue 2, 2013, Pages 108-116

  Murugaiyan, Gopal ^a   Saha, Bhaskar ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Angiogenesis; IL 27; Immunosuppression; Immunotherapy; Tumor immunity

Indexed keywords

CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 130; GRANULOCYTE CHEMOTACTIC PROTEIN 2; GRANZYME B; HYPOXIA INDUCIBLE FACTOR; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 27; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; RANTES; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL KILLING; CELL MIGRATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; INTERFERON INDUCTION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-17; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES, REGULATORY;

EID: 84873182414     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.12.002     Document Type: Review

References (95)

1. Zitvogel L., et al. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6:715-727.
2. Murugaiyan G., et al. Reversal of tumor induced dendritic cell paralysis: a treatment regimen against cancer. Curr. Immunol. Rev. 2006, 2:261-272.
3. Kelsall B.L., et al. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann. N. Y. Acad. Sci. 1996, 795:116-126.
4. Schoenberger S.P., et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
5. Murugaiyan G., et al. CD40-induced countercurrent conduits for tumor escape or elimination?. Trends Immunol. 2007, 28:467-473.
6. Curtsinger J.M., et al. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 2003, 197:1141-1151.
7. Murugaiyan G., et al. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J. Immunol. 2007, 178:2047-2055.
8. Ryffel B. Interleukin-12: role of interferon-γ in IL-12 adverse effects. Clin. Immunol. Immunopathol. 1997, 83:18-20.
9. Leonard J.P., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997, 90:2541-2548.
10. + T cells. Immunity 2002, 16:779-790.
11. Murugaiyan G., et al. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-γ limits IL-17 mediated autoimmune inflammation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11495-11500.
12. Shinohara M.L., et al. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008, 29:68-78.
13. Schnurr M., et al. Extranuclear nucleotide signalling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for cAMP pathway. Blood 2005, 105:1582-1589.
14. Pirhonen J., et al. IFN-α regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages. J. Leukoc. Biol. 2007, 82:1185-1192.
15. Remoli M.E., et al. IFN-β modulates the response to TLR stimulation in human DC: involvement of IFN regulatory factor-1 (IRF-1) in IL-27 gene expression. Eur. J. Immunol. 2007, 37:3499-3508.
16. Schuetze N., et al. IL-12 family members: differential kinetics of their TLR4-mediated induction by Salmonella enteritidis and the impact of IL-10 in bone marrow-derived macrophages. Int. Immunol. 2005, 17:649-659.
17. Liu J., et al. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-γ-mediated pathways. J. Exp. Med. 2007, 204:141-152.
18. Wirtz S., et al. EBV-induced gene 3 transcription is induced by TLR signalling in primary dendritic cells via NF-κB activation. J. Immunol. 2005, 174:2814-2824.
19. Liu J., et al. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J. Biol. Chem. 2004, 279:55609-55617.
20. Molle C., et al. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J. Immunol. 2007, 178:7607-7615.
21. + T cells against exogenous viral antigens. Eur. J. Immunol. 2006, 36:2046-2060.
22. Sekar D., et al. Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur. J. Immunol. 2012, 42:1585-1598.
23. Pflanz S., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 2004, 172:2225-2231.
24. Scheller J., et al. No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys. Res. Commun. 2005, 326:724-728.
25. Villarino A.V., et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 2005, 174:7684-7691.
26. Seita J., et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008, 111:1903-1912.
27. Diegelmann J., et al. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J. Biol. Chem. 2012, 287:286-298.
28. Liu L., et al. IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand. J. Immunol. 2008, 68:22-29.
29. Matsui M., et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 2009, 69:2523-2530.
30. + T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. 2005, 175:1686-1693.
31. + T lymphocytes and promotes their development into Tc1 cells. Eur. J. Immunol. 2011, 41:47-59.
32. + T cells induces granzyme B in an autocrine manner. Immunol. Cell Biol. 2012, 90:831-835.
33. Spolski R., Leonard W.J. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr. Opin. Immunol. 2008, 20:295-301.
34. Hisada M., et al. Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64:1152-1156.
35. Chiyo M., et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 2005, 115:437-442.
36. + T cells. J. Immunol. 2004, 173:7170-7182.
37. Shinozaki Y., et al. Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int. J. Cancer 2009, 124:1372-1378.
38. Salcedo R., et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 2009, 182:4328-4338.
39. Takeda A., et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 2003, 170:4886-4890.
40. + T cells. J. Immunol. 2004, 173:3871-3877.
41. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15047-15052.
42. Artis D., et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 2004, 173:5626-5634.
43. Yoshimoto T., et al. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 2007, 179:4415-4423.
44. Liao D., et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4:e7965.
45. Tassi E., et al. Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients. PLoS ONE 2009, 4:e7234.
46. Huber M., et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 2008, 20:223-234.
47. Wojno E.D., et al. A role for IL-27 in limiting T regulatory cell populations. J. Immunol. 2011, 187:266-273.
48. Villarino A.V., et al. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 2006, 176:237-247.
49. Yoshimoto T., et al. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 2008, 180:6527-6535.
50. Shimizu M., et al. Antiangiogenic and antitumor activities of IL-27. J. Immunol. 2006, 176:7317-7324.
51. Feng X.M., et al. Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator. Hum. Immunol. 2007, 68:965-972.
52. Cocco C., et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 2010, 16:4188-4197.
53. Canale S., et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 2011, 25:1815-1824.
54. -/- mice. Clin. Cancer Res. 2012, 18:1630-1640.
55. Cocco C., et al. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia 2012, 26:1365-1374.
56. Oniki S., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006, 66:6395-6404.
57. Keyser J., et al. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp. Dermatol. 2004, 13:380-390.
58. Weiss J.M., et al. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin. Biol. Ther. 2007, 7:1705-1721.
59. + T cells. J. Immunol. 2009, 183:2435-2443.
60. Diveu C., et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J. Immunol. 2009, 182:5748-5756.
61. Stumhofer J.S., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 2006, 7:937-945.
62. Murugaiyan G., Saha B. Pro-tumor vs anti-tumor functions of IL-17. J. Immunol. 2009, 183:4169-4175.
63. Tartour E., et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999, 59:3698-3700.
64. Numasaki M., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
65. Takahashi H., et al. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett. 2005, 98:189-193.
66. Wakita D., et al. Tumor-infiltrating IL-17-producing γδ T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 2011, 40:1927-1937.
67. Numasaki M., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 2005, 175:6177-6189.
68. Su X., et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 2010, 184:1630-1641.
69. Ilarregui J.M., et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 2009, 10:981-991.
70. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26:281-290.
71. Facciabene A., et al. Tumour hypoxia promotes tolerance and angiogenesis via Ccl28 and T Reg cells. Nature 2011, 475:226-230.
72. Curiel T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
73. Gobert M., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69:2000-2009.
74. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol. Oncol. 2008, 110:216-221.
75. Motz G.T., Coukos G. Angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11:702-711.
76. Greenhough A., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
77. + T cells. J. Immunol. 2005, 175:1483-1490.
78. + T regulatory cell activities in lung cancer. Cancer Res. 2005, 65:5211-5220.
79. 2. Gut 1994, 35:675-678.
80. Yuan X.L., et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin. Immunol. 2010, 134:277-288.
81. Ho M.Y., et al. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J. Immunol. 2009, 183:6217-6226.
82. Pot C., et al. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin. Immunol. 2011, 23:438-445.
83. Awasthi A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007, 8:1380-1389.
84. Hall A.O., et al. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 2012, 37:511-523.
85. Mumm J.B., et al. IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 2011, 20:781-796.
86. + T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012, 72:3570-3581.
87. Mocellin S., et al. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 2005, 78:1043-1051.
88. Wang S., et al. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1 (IL-27R) deficiency. J. Immunol. 2007, 179:6421-6428.
89. Karakhanova S., et al. IL-27 renders DC immunosuppressive by induction of B7-H1. J. Leukoc. Biol. 2011, 89:837-845.
90. Hirahara K., et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012, 36:1017-1030.
91. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
92. Wong M.T., et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol. Cell Biol. 2010, 88:624-631.
93. Murugaiyan G., et al. IFN-γ limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J. Immunol. 2012, 189:5277-5283.
94. Young A., et al. Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27. J. Immunol. 2012, 189:2079-2083.
95. Purwar R., et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat. Med. 2012, 18:1248-1253.